Targets › MCAM
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. (UniProt, P43121)
Open in Phaseline: the race on MCAM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Essen Biotech | CD146/HER2 CAR-T cells Dual CAR-T cells targeting CD146 and HER2 | MCAM, ERBB2 | Phase 1 | Sarcoma | Dec 2027 |
Sarcoma (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.